Jpmorgan Chase & CO Allovir, Inc. Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Allovir, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 8,157 shares of ALVR stock, worth $79,938. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,157

Previous 2,178 274.52%

Holding current value

$79,938

Previous $1,000 200.0%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$0.4 - $1.01 $2,391 - $6,038	5,979 Added 274.52%	8,157 $3,000
Q3 2024 Dec 26, 2024	SELL	$0.7 - $0.82 $3,208 - $3,758	-4,584 Reduced 67.79%	2,178 $1,000
Q3 2024 Nov 08, 2024	SELL	$0.7 - $0.82 $3,208 - $3,758	-4,584 Reduced 67.79%	2,178 $1,000
Q2 2024 Dec 26, 2024	BUY	$0.72 - $0.82 $3,300 - $3,758	4,584 Added 210.47%	6,762 $4,000
Q2 2024 Aug 12, 2024	SELL	$0.72 - $0.82 $16,863 - $19,206	-23,422 Reduced 77.6%	6,762 $4,000
Q1 2024 Dec 26, 2024	BUY	$0.64 - $0.78 $17,923 - $21,844	28,006 Added 1285.86%	30,184 $22,000
Q1 2024 May 10, 2024	SELL	$0.64 - $0.78 $214,229 - $261,091	-334,733 Reduced 91.73%	30,184 $22,000
Q4 2023 Dec 26, 2024	BUY	$0.68 - $2.39 $246,662 - $866,946	362,739 Added 16654.68%	364,917 $248,000
Q4 2023 Feb 12, 2024	SELL	$0.68 - $2.39 $471,288 - $1.66 Million	-693,071 Reduced 65.51%	364,917 $248,000
Q3 2023 Nov 14, 2023	SELL	$2.15 - $3.64 $78,980 - $133,715	-36,735 Reduced 3.36%	1,057,988 $2.27 Million
Q2 2023 Aug 11, 2023	BUY	$3.17 - $5.82 $345,894 - $635,049	109,115 Added 11.07%	1,094,723 $3.72 Million
Q1 2023 May 18, 2023	BUY	$3.94 - $7.05 $93,748 - $167,747	23,794 Added 2.47%	985,608 $3.88 Million
Q1 2023 May 11, 2023	SELL	$3.94 - $7.05 $929 - $1,663	-236 Reduced 0.02%	961,814 $3.79 Million
Q4 2022 Feb 13, 2023	BUY	$4.7 - $9.98 $1.66 Million - $3.52 Million	352,919 Added 57.94%	962,050 $4.94 Million
Q3 2022 Nov 14, 2022	SELL	$4.13 - $8.79 $688,371 - $1.47 Million	-166,676 Reduced 21.48%	609,131 $4.81 Million
Q2 2022 Aug 11, 2022	BUY	$3.26 - $7.06 $38,790 - $84,006	11,899 Added 1.56%	775,807 $3.03 Million
Q1 2022 May 11, 2022	BUY	$6.75 - $13.52 $1.12 Million - $2.24 Million	165,711 Added 27.7%	763,908 $5.16 Million
Q4 2021 Feb 10, 2022	SELL	$12.94 - $25.99 $1.93 Million - $3.88 Million	-149,302 Reduced 19.97%	598,197 $7.74 Million
Q3 2021 Nov 12, 2021	BUY	$16.97 - $25.06 $12.7 Million - $18.7 Million	747,499 New	747,499 $18.7 Million

Others Institutions Holding ALVR

# of Institutions

Shares Held

21.1M

Call Options Held

41K

Put Options Held

100

View Full List

About Allovir, Inc.

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $912M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

More about ALVR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Allovir, Inc. Transaction History